TWO · 4126.TWO
Pacific Hospital Supply Co., Ltd
NT$75.50+NT$0.20 (+0.27%)
Pacific Hospital Supply Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 15.83% below the high.
Loading market information…
TWO · 1788.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Hi-Clearance Inc.’s quoted price sits in the lower half of its reported 52-week range, 7.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Hi-Clearance Inc.’s forward annual dividend is NT$7.00 per share, paid annual. The forward yield is 5.51% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hi-Clearance Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1989 and headquartered in New Taipei City, Taiwan, Hi-Clearance Inc. is a prominent supplier of medical devices and associated services throughout Taiwan. The company's comprehensive product range addresses various healthcare sectors, including renal care, cardiac health, radiation therapy, dentistry, oral surgery, and metabolic conditions. Its medical offerings encompass vital equipment such as dialyzers, dialysis machines, and reverse osmosis (RO) systems, complemented by essential consumables and pharmaceutical products. Hi-Clearance also provides specialized devices for interventional cardiology, radiology, and vascular surgery. For the dental field, it supplies consumables, implant materials, and equipment. Furthermore, the company offers blood glucose monitors, along with their related consumables and nutritional products. Beyond product provision, Hi-Clearance Inc. delivers extensive hemodialysis management services and specializes in the development and operation of dialysis centers. Diversifying its business, the company also engages in the distribution and servicing of healthy and natural beverages, and acts as an OEM provider for beverage raw materials and concentrates.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:50 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$75.50+NT$0.20 (+0.27%)
Pacific Hospital Supply Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 15.83% below the high.
NT$88.10-NT$0.40 (-0.45%)
Formosa Optical Technology Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.05% below the high.
NT$65.60+NT$5.30 (+8.79%)
Bionime Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.01% below the high.
NT$47.55+NT$4.30 (+9.94%)
SciVision Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
NT$35.10-NT$1.00 (-2.77%)
Maxigen Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.33% below the high.
NT$23.35-NT$0.55 (-2.3%)
Wellell Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.85% below the high.
NT$51.50-NT$1.50 (-2.83%)
Medimaging Integrated Solution Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.94% below the high.
NT$16.80-NT$0.25 (-1.47%)
OK Biotech Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 8.75% below the high.
